A
biosimilar medication called CT-P13 was accepted by the European Medicines
Agency to enhance symptoms of ankylosing spondylitis (AS) — including ailment
movement, incapacity, and mobility with a drug named infliximab, otherwise
called Remicade.
As
per a study introduced at the European League Against Rheumatism Annual
Congress, CT-P13 is the world's first biosimilar monoclonal immune response to
get support and gives a less expensive, more financially savvy alternative for
patients with AS. Biosimilars are generic versions of biologic medication.
By
demonstrating comparable efficacy and safety, the results of our clinical
trials should give physicians confidence in using CT-P13 as an alternative
treatment option in AS patients,” Park said. “This is good news for patients
who may previously have had limited access to costly antibody
biopharmaceuticals.”
“Regulated
introduction of biosimilars into the market has been forecasted to increase
access to much needed biologic medicines and reduce costs,” the report stated.
"The biologic medicines market is expected to grow to $190-200 billion by
2015, with biosimilars a small but growing proportion at $2-2.5 billion.”
One
big challenge in front of the approved Biosimilars is not only its similar
properties to those traditional medicines that it acts as an alternative, but
also being highly effective and safe to be used.
There
is a latest report on global biosimilar market, which forecasts the market to
reach $35 billion by 2020. Biosimilars are definitely better alternatives to biologics.
